Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,664 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: High Dose Drug A Clear all

Conditions: Healthy Participants
Interventions: PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Formulation Bridging, Food Effect
Interventions: PBI-200 Tablet, PBI-200 Capsule, PBI-200 Suspension; Drug
Lead sponsor: Pyramid Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Non-Hodgkin Lymphoma, Large B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: High Altitude Pulmonary Hypertension
Interventions: Aminophylline, Ambrisentan, Aminophylline plus ambrisentan; Drug
Lead sponsor: Thies Schroeder; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diverticulitis
Interventions: Partial Colectomy, Medical Management; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 29
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 24 more

Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions: Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Hollywood, Florida • Miami, Florida

Conditions: Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Tay Sachs Disease, Sandhoffs Disease, Wolman Disease, I-Cell Disease, Sanfilippo Syndrome, GM1 Gangliosidosis
Interventions: Clofarabine, Total body Irradiation, Melphalan, Hematopoietic Stem Cell Transplantation, Alemtuzumab, mycophenylate mofetil, Cyclosporine A, Hydroxyurea; Drug · Procedure · Biological + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Facet Joints; Degeneration, Back Pain, Facet Joint Pain
Interventions: Alocyte low dose, Alocyte medium dose, Alocyte high dose; Drug
Lead sponsor: Alimorad Farshchian; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: North Miami, Florida

Conditions: Cognitive Function, Video Gamers
Interventions: Phaeosol low dose, Phaeosol high dose, Placebo; Dietary Supplement
Lead sponsor: Microphyt; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Verruca Vulgaris, Warts, Common Wart
Interventions: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 9 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Emavusertib, Venetoclax; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 12
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions: Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo; Diagnostic Test · Behavioral · Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 8 Years to 12 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Lakeland, Florida • Maitland, Florida • Tampa, Florida

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Granada Hills, California • Northridge, California • Torrance, California + 5 more

Conditions: Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nicotine Dependence
Interventions: Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2023
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions: Azacitidine, Pevonedistat; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Chordomas, Chordoma
Interventions: Pembrolizumab, Pemetrexed Phase 2; Drug
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Coronary Artery Disease
Interventions: High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires; Drug · Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 2,476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 80
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more

Conditions: Chronic Gout
Interventions: SEL-212 low-dose, SEL-212 high-dose, Normal Saline; Drug · Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more

Conditions: COVID-19
Interventions: FT516; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 76 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Cancer, High Risk
Interventions: 68Ga-PSMA; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 21 Years and older · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Squamous Cell Carcinoma
Interventions: PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable); Drug
Lead sponsor: Privo Technologies; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Duarte, California • Miami, Florida • Chicago, Illinois + 1 more

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Preeclampsia
Interventions: Pravastatin, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas

Search by objective public record fields.

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers

Comparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

HSCT for High Risk Inherited Inborn Errors

Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain

Efficacy of a Microalgae Extract PhaeoSOL Combined With Natural Stimulant on Cognitive Function and Gaming Performance of Video Gamers

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

Impact of Liraglutide 3.0 on Body Fat Distribution

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Pembrolizumab and Pemetrexed for Progressive Chordoma

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

68 Ga-PSMA for High Risk Prostate Cancer

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Safety Study of TPI-287 to Treat CBS and PSP

Pravastatin for Prevention of Preeclampsia